Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Global Restructuring Plan, It’s Full Steam Ahead In China For Merck

This article was originally published in PharmAsia News

Executive Summary

Days after announcing a global restructuring plan, Merck CEO Ken Frazier visits Beijing to pledge $6 million toward the second phase of C-MAP, a public-private partnership with the Chinese government on HIV/AIDS. Frazier’s trip underscores the continuing importance of China to Merck despite a company-wide plan to cut 8,500 positions and reduce operating costs by $2.5 billion by 2015.

You may also be interested in...



Merck’s Big Move: Massive Cost Cuts And R&D Changes Ahead

Merck will cut 8,500 positions and reduce operating costs by $2.5 billion by 2015 to jumpstart growth in the midst of slowing sales and several late-stage pipeline setbacks. A key initiative is to recharge R&D by reinvesting in key projects and increasing business development activities.

First Spring Sign: Chinese Vaccines Maker Gets $290m Funding

With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.

Podcast: Biopharma's Moment To Deliver On Coronavirus And The People's Hope

Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.

Topics

Related Companies

UsernamePublicRestriction

Register

SC082687

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel